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Neuropsychiatric (NP) manifestations pose diagnostic
and therapeutic challenges in systemic lupus erythema-
tosus (SLE). Less than one-third of these events can be
directly attributed to SLE; accordingly attribution to SLE
remains a considerable challenge. Increased generalized
SLE disease activity or damage, previous or concurrent
major neuropsychiatric SLE (NPSLE) events, and persis-
tently positive moderate-to-high antiphospholipid anti-
body titers are established risk factors. NPSLE patients
have increased genetic burden and novel genomic
approaches are expected to elucidate its pathogenesis. In
animals with disturbed blood-brain barrier, autoantibodies
against the NR2 subunits of the N-methyl-D-aspartate
receptor and 16/6 idiotype antibodies, may cause diffuse
NP manifestations through neuronal apoptosis or brain
inflammation; data in humans are still circumstantial. In
NPSLE, advanced neuroimaging uncovers structural and
metabolic abnormalities in brain regions with normal
appearance on conventional magnetic resonance imaging.
The European League Against Rheumatism (EULAR)
has published evidence and expert based opinion for the
management of NPSLE(1).. According to them, diagnostic
evaluation is guided by the presenting manifestation with
MRI used to visualize brain or spinal pathologies. For
neuropsychiatric events believed to reflect an immune or
inflammatory process, or when these events occur in the
context of active generalized disease, evidence (primarily
from uncontrolled studies) supports the use of glucocorti-
coids alone or in combination with immunosuppressive
therapy. In refractory cases, uncontrolled studies suggest a
beneficial role of rituximab. Antiplatelet and/or anticoagu-
lation therapy is recommended for NPSLE manifestations
related to antiphospholipid antibodies, especially for
thrombotic cerebrovascular disease. For the future, we
anticipate that novel biomarkers and advanced neuroima-
ging tests will better define the underlying pathologic
mechanisms of SLE-related neuropsychiatric disease, and
help guide therapeutic decisions.
Disclosure of interest
None declared.
Published: 5 December 2013
doi:10.1186/1546-0096-11-S2-I4
Cite this article as: Boumpas: PReS13-SPK-1283: Pathogenesis, diagnosis
and management of neuropsychiatric SLE. Pediatric Rheumatology 2013
11(Suppl 2):I4.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
University of Athens, Athens, Greece
Boumpas Pediatric Rheumatology 2013, 11(Suppl 2):I4
http://www.ped-rheum.com/content/11/S2/I4
© 2013 Boumpas; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
